Programmdetails

Postersitzungen

Kardiomyopathien

Samstag, 27. September | 09:45 - 11:15 Uhr | Posterbereich 7

Vorsitz/Chair: Christoph Birner (Amberg), Stephanie Schwarting (München)

Agenda

(P676)
Corticosteroid treatment in patients with newly diagnosed clinically silent cardiac sarcoidosis is associated with significantly improved long-term outcomes
J. Mörike (Ulm)
(P677)
Baseline patient-reported outcome results in patients with heart failure initiated on dapagliflozin: results of 2nd interim analysis of the non-interventional EVOLUTION-HF DEallEF study
M. Paul (Münster)
(P678)
Impact of guideline-directed medical therapy on LVEF-recovery in de novo HFrEF in females: analysis from a bicentric patient cohort
F. Post (Frankfurt am Main)
(P679)
Divergent Ventricular Responses in HFpEF Call for Dual-Sided Therapeutic Strategies
H. Osman (Bochum)
(P680)
Impact of Mavacamten on Bilateral Atrial and Ventricular Remodeling in Obstructive Hypertrophic Cardiomyopathy - Echocardiographic Analysis of a Real-World Cohort
F. Becker (München)
(P681)
Vericiguat in der realen Welt: Welche Patient:innen sprechen an?
P. Horn (Bonn)
(P682)
Real-World Disease Progression in Transthyretin Cardiac Amyloidosis: An Analysis Based on Consensus-Recommended Monitoring Parameters
Y. Metodiev (München)
(P683)
Tafamidis induces improvement of right ventricle-to-pulmonary artery coupling in patients with transthyretin amyloid cardiomyopathy
J. Mörike (Ulm)
Diese Seite teilen